CD4 down-regulation by human immunodeficiency virus type 1 (HIV-1) Nef protein is a key function for virus virulence. This activity may be mediated by a direct Nef-CD4 interaction. We investigated the formation, in situ, of such a complex between proteins using bioluminescence resonance energy transfer technology and coimmunoprecipitations. Our data clearly demonstrate that Nef and CD4 interact in intact human cells. Moreover, our results clearly indicate that the dileucine motif of the CD4 cytoplasmic domain, critical for the Nef-induced CD4 down-regulation, is not implicated in the Nef/CD4 complex formation in the cellular context.
The myristoylated Nef protein encoded by primate immunodeficiency viruses is essential for efficient viral replication and pathogenesis in their hosts (17, 21, 28, 30, 43) . This viral protein is abundantly produced at the early stages of viral replication and displays variety of functions. Nef interferes with signal transduction pathways (19, 40, 44, 47, 54) ; downmodulates CD4 (18, 24, 25, 38, 39) , major histocompatibility complex class I (MHC-I) (35, 46) , CD3 (7, 27, 53) , and CD28 (6, 50) receptors; and also enhances virion infectivity (13, 15, 45, 56) and replication capacity (2, 15, 37, 49) . Several steps of the Nef-mediated CD4 down-regulation molecular mechanism are understood, like the recruitment of the 2 chain of the adapters (11, 16, 20, 22, 32, 34, 38) and the coatomers (8, 26, 39) to redirect membrane CD4 to the lysosomal degradation pathway. However, the implication of a Nef/CD4 complex remains putative. This complex was sensed with the yeast twohybrid system (42) and detected in vitro using truncated proteins (23) . Through recent nuclear magnetic resonance (NMR) experiments (41) , the dissociation constant was found to be in the submicromolar range. Furthermore, previous in vitro works (1, 41, 42) have revealed that the L 413 L 414 motif of the CD4 cytoplasmic domain was critical in vitro for the CD4/Nef complex formation and the Nef-induced down-regulation. Up to today, the formation of this complex has never been revealed in situ with full-length Nef and CD4 proteins and the importance of the domains depicted in vitro have not been confirmed in vivo. To directly study in living human cells the ability of Nef to interact with the CD4 receptor, we use bioluminescence resonance energy transfer (BRET) (4, 10, 14, 36, 55) in HEK-293 cells. In this technique, the putative protein partners are respectively fused to Renilla luciferase (Rluc), and to enhanced yellow fluorescent protein (EYFP). In the presence of the substrate coelenterazine and upon its degradation by Rluc, the luminescence is transferred from Rluc to EYFP, with an efficiency depending on the proximity (Ͻ5 nm) of the fusion proteins. Protein-protein interactions are then highlighted through EYFP fluorescence emission. BRET is applicable to living cells. In order to verify the impact of the L 413 L 414 motif of CD4 on the possible Nef-CD4 association, we also studied the CD4 L 413 L 414 -A 413 A 414 mutant (CD4 414AA). With this technique, we demonstrate that Nef and CD4 interact in human cells. Surprisingly, the CD4 414AA mutant, which was presumed not to interact with Nef, is still recognized by Nef. To confirm these results, we perform coimmunoprecipitation assays in HEK-293 cells, with full-length native proteins, done after stabilization of the complex with a cross-linking reagent. These experiments reveal a direct interaction between Nef and CD4. Moreover we confirm that the L 413 L 414 motif of CD4 is not implicated in the formation of this interaction. Finally, we perform BRET assays with nontagged CD4 or CD4 414AA as competitors of the fluorescent receptors. The two molecules are able to abolish the energy transfer between Nef-Rluc and CD4-EYFP or CD4 414AA-EYFP, revealing the specificity of the interactions we have observed.
The BRET and coimmunoprecitation assays were performed in HEK-293 cells (ATCC CRL-1573) to detect the putative Nef/CD4 and Nef/CD4 414AA complexes to evaluate the influence of the dileucine motif mutation in CD4 (413A,414A) on the interaction. These embryonic kidney cells, from human lineage, can be efficiently transfected using a calcium phosphate method (51, 52); they do not express CD4. Thus, no competition between endogenous CD4 and CD4-EYFP molecules should alter the efficiency of energy transfer between the tagged Nef and CD4.
The coding sequences of NefLai (HIV Databases, accession no. K02013) and CD4 were respectively inserted into the pCi-Neo (Promega) and pcDNA3 (Invitrogen) expression vectors. The pCML/CD4 414AA plasmid vector allowing the expression of the mutated CD4 was a gift from Didier Trono. In a preliminary experiment, to verify if a protein-protein interaction can be detected in our model, the well-documented Nef self-association (5, 29, 31) was chosen as a positive control. First, the NefLai-Rluc fusion protein was generated. The Rluc enzyme (M1 to Q311; Clontech) was fused with a four-residue spacer (GLAT) to the carboxy terminus of the full-length NefLai protein (M1 to C206; HIV Databases, accession no. K02013). To optimize protein expression, the gene of this fusion protein was cloned into the pCi-Neo vector, under the control of the immediate-early cytomegalovirus (CMV) promoter, generating the pCi-Neo/NefLai-Rluc plasmid. Using the same strategy, the EYFP (M1 to L275; Clontech) was added to the NefLai protein (M1 to C206), with a two-methionine spacer. The neflai-eyfp gene was then inserted into the pCI-Neo vector to generate the pCi-Neo/NefLai-EYFP plasmid. The CD4-EYFP protein was generated by fusing the EYFP (M1 to L275) with a four-residue spacer (PVAT) to the carboxy-terminal extremity of the human CD4 receptor (M1 to R450; SwissProt, accession no. P01730) and was cloned into pcDNA3, under control of the CMV promoter (pcDNA3/ CD4-EYFP). The pCi-Neo/CD4 414AA-EYFP was constructed by fusing the cd4 414AA gene with a two-residue (VD) spacer to the EYFP gene in the pCi-Neo plasmid.
Due to the presence of a myristol group, the Nef protein is mostly anchored at the plasma membrane, but some of it is also free in the cytoplasm. Thus, results obtained with two negative controls are reported. First, as a negative control of proteins anchored in the plasma membrane, we used the pHis/ ␤2AdrR-EYFP plasmid (kindly provided by M. Bouvier), which encodes the ␤2-adrenergic receptor fused to the EYFP, with pCi-Neo/NefLai-Rluc. Second, as a free cytoplasmic protein control, we used a plasmid containing two independent expression cassettes coding NefLai-Rluc and EYFP, under control of the CMV immediate-early promoter. For this, the CD4 coding sequence was eliminated from the pcDNA3/CD4-EYFP, and then the resulting expression cassette encompassing the CMV promoter and the eyfp was inserted into pCi-Neo/ NefLai-Rluc to generate pCi-Neo/NefLai-Rluc/EYFP.
To determine in which cellular compartment the different fusion proteins are expressed in our model, we studied their localization into the HEK-293 cells. The cells (6.5 ϫ 10 4 ) were seeded in eight-well culture slides and transfected the day after with 1 g of the plasmid coding for the ␤2Adr-EYFP, NefRluc, Nef-EYFP, CD4-EYFP, or CD4 414AA-EYFP fusion proteins. Two days posttransfection, the cells expressing NefRluc were fixed with 1.5% paraformaldehyde and permeabilized in 1ϫ Permwash (Pharmingen). The Nef-Rluc protein was recognized using the mouse monoclonal antibody maTG020 (kindly provided by Transgene SA) directed against Nef and labeled with a fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse antibody (Sigma). The cells synthesizing fluorescent proteins were only fixed. Localization of the proteins was then established upon observation of cell fluorescence with a Zeiss LSM 510 confocal microscope (Fig. 1A) . The ␤2Adr-EYFP and the two fluorescent variants of the CD4 were essentially expressed at the plasma membrane. The Nef-Rluc and Nef-EYFP were found mainly at the plasma membrane; some patches were also detected in the cytoplasm. Thus, proteins of interest are correctly addressed in the HEK-293 cells. The supposed mechanism by which Nef affects the CD4 cell surface expression implies the recognition of the receptor by the viral protein at the plasma membrane. In order to observe if the Nef protein could colocalize with the CD4 and CD4 414AA in our model, cells were cotransfected to express simultaneously Nef or Nef-Rluc and one of the two CD4 unlabeled variants. Two days posttransfection, the HEK-293 cells were fixed and permeabilized. The CD4 receptors were labeled with an anti-CD4-PC5 antibody (Pharmingen), and Nef proteins were detected as previously described. The CD4 and CD4 414AA proteins were mostly localized at the plasma membrane; as seen by confocal microscopy (Fig. 1B ) the two Nef proteins were also found principally at the cell periphery. Finally, the colocalization patterns clearly indicated that Nef and Nef-Rluc colocalize with CD4 and CD4 414AA at the plasma membrane in our expression model. Thus, a Nef-CD4 association might occur at the plasma membrane in our cells.
To verify the functionality of Nef fusion proteins, the Nefinduced CD4 down-regulation was evaluated in the HEK-293 cells. The cells (1 ϫ 10 6 ) were cotransfected with 0.5 g of plasmids coding for CD4 or CD4 414AA receptors and with 4.5 g of plasmids containing the coding sequences of wild-type or fusion Nef proteins. The CD4 cell surface expression was determined 24 h after transfection by flow cytometry on cells labeled with an anti-CD4-PC5 antibody (Fig. 2) . As expected, the Nef protein efficiently down-regulates wild-type CD4 (determined as reduction of CD4 cell surface expression) and has no effect on the CD4 414AA surface expression. This confirms the importance of the L 413 L 414 motif for the CD4 down-regulation by Nef. These experiments also reveal that the fusion of Nef with EYFP or Rluc reduces the potency of Nef to downregulate CD4 without abolishing it. Moreover, the two proteins do not acquire the ability to down-regulate the CD4 414AA mutant. Thus, these proteins can be used to perform BRET assays, in order to detect the putative Nef-CD4 interaction. To verify that the fusion of EYFP with CD4 does not alter the Nef-induced CD4 down-regulation, the presence of CD4-EYFP at the plasma membrane in Nef-expressing cells was studied by flow cytometry. Down-regulation of CD4-EYFP was not observed, either with the Nef wild type or with Nef fusion proteins (Fig. 2) . The Nef-mediated CD4 internalization is a multistep process, and a lack of down-regulation may not necessary imply that the putative Nef-CD4 association does not occur. Therefore, CD4-EYFP was nevertheless used for BRET experiments to check for a direct binding of Nef with CD4.
The BRET assay was first validated in our model using the Nef-Rluc/Nef-EYFP pair. To show Nef homo-oligomerization, HEK-293 cells (1 ϫ 10 7 ) were transfected to express the Nef-Rluc/EYFP, Nef-Rluc/␤2AdrR-EYFP, or Nef-Rluc/Nef-EYFP pairs. The cells were resuspended 48 h posttransfection in HEPES-bovine serum albumin medium (51) at 10 7 cells/ml, and 10 M of the Rluc substrate was added, (coelenterazine-f; Bioprobe). Emission spectra were measured using a spectrofluorimeter (PTI, OC-4000, MD-5020) and normalized (Fig.  3A) . Fluorescence and luminescence measurements were performed at 37°C to preserve cell metabolism and plasma membrane fluidity. In the case of the control cells expressing NefLai-Rluc and EYFP or ␤2AdrR-EYFP, which do not in- teract, only Rluc luminescence emission is expected. Indeed, no significant difference was detected between the signals of the two negative controls. In contrast, in cells producing NefLai-Rluc and NefLai-EYFP, which can oligomerize, Rluc and EYFP emission signals are expected. Then, by subtracting the ␤2AdrR-EYFP negative control spectrum from the one measured in cells expressing the two Nef fusion proteins, we obtain a transfer spectrum that was compared to the EYFP emission spectrum (Fig. 3B) . The Nef-Rluc/Nef-EYFP transfer spectrum was indeed identical to the EYFP emission spectrum measured after excitation at 480 nm. Thus, a physical proximity of Nef-Rluc and Nef-EYFP can be detected by BRET. This highlights Nef homo-oligomerization. Our experimental system allows the detection of protein-protein interactions. Then the association of Nef with CD4 was studied using this technique. For this, HEK-293 cells were transfected to produce the Nef-Rluc/CD4-EYFP pair and Nef-Rluc/␤2Adr-EYFP as a negative control. Emission spectra were acquired as described above (Fig. 4A) , and the Nef-Rluc/CD4-EYFP transfer spectrum was compared to the EYFP emission spectrum (Fig. 4B) . The transfer signal corresponded to the EYFP fluorescence signal. This indicates that we detected the Nef-CD4 interaction. Furthermore, we analyzed, in the BRET assay, the binding ability of Nef-Rluc for CD4 414AA-EYFP (Fig. 4C and D) . In these assays, an EYFP emission was also observed, indicating that the Nef protein can also interact with the mutated CD4 receptor.
In an attempt to visualize the Nef-CD4 and Nef-CD4 414AA associations by a second method, cells were treated with a cross-linking reagent to stabilize protein complexes before co- on October 15, 2017 by guest http://jvi.asm.org/ maTG020 or RPA-T4 (Pharmingen) monoclonal antibodies, respectively, directed against human immunodeficiency virus type 1 (HIV-1) Nef and CD4. The immune complexes were incubated for 1 h with protein A/G plus agarose and centrifuged, and the pellets were washed six times in Tris-buffered saline -0.3% CHAPS, pH 7.4. The proteins were resolved by 12.5% SDS-acrylamide gel electrophoresis, and the gel was processed for fluorography (Fig. 5) . Nef was specifically immunoprecipitated by maTG020; a background product of about 46 kDa was observed in all samples (Fig. 5A) . In cells cotransfected with Nef and CD4 genes, we found that a protein with a molecular weight similar to that of CD4 coprecipitated with Nef. The same result was obtained with the CD4 414AA mutant (Fig. 5A ). These data demonstrate that wild-type Nef and CD4 interact in human cells. Moreover, in this cellular context, the dileucine motif of the CD4 cytoplasmic domain, critical for the Nef-induced CD4 down-regulation, does not appear to be involved in the Nef-CD4 binding. To confirm that the proteins immunoprecipitated with Nef were effectively CD4 or CD4 414AA, immunoblotting experiments were performed. For this, 10 million HEK-293 cells were transfected to express CD4 or to produce Nef and one of the two CD4 variants. Two days later, the cells were submitted to DSP treatment and lysed, and immunoprecipitation directed against Nef or CD4 was performed. The immune complexes collected as described above were separated by electrophoresis under denaturing conditions and transferred on a polyvinylidene difluoride (PVDF) membrane (Amersham). A chemiluminescent detection of CD4 was then performed with a rabbit polyclonal antibody directed against this receptor (Santa Cruz) and an antibody against rabbit immunoglobulins coupled to horseradish peroxidase (Amersham). These experiments reveal that CD4 and CD4 414AA are specifically immunoprecipitated in the presence of Nef (Fig. 5B) , indicating that the CD4 receptor and its mutant interact with Nef. Moreover, the ability of Nef to interact with CD4-EYFP was also studied using the same procedure ( Fig. 5A and B) . These assays revealed that CD4 and CD4 414AA fused to the EYFP can still coimmunoprecipitate with Nef. Thus, the abrogation of the Nef-induced CD4 down-regulation observed previously with the CD4-EYFP is presumably the consequence of a steric obstruction which inhibits the recruitment of a critical protein for the down-regulation, without disrupting the Nef-CD4 interaction.
To control the specificity of the interactions observed between NefLai-Rluc and CD4-EYFP, or CD4 414AA-EYFP, competition experiments were performed using unlabeled CD4 and CD4 414AA receptors. Thus, HEK-293 cells were cotransfected to express Nef-Rluc/CD4-EYFP, Nef-Rluc/CD4 414AA-EYFP, or Nef-Rluc/␤2AdrR-EYFP pairs in presence of pCi-Neo or one of the two untagged CD4 variants. Finally, the Nef-Rluc/CD4-EYFP transfer spectra, recorded in the presence or in the absence of nontagged CD4 receptors, were compared to the EYFP emission spectrum (Fig. 6A) . In the absence of wild-type receptors, BRET was observed. However, in the presence of one or the other of the two competitors, the Nef-Rluc/CD4-EYFP transfer was totally abolished. The same experiments were performed with the Nef-Rluc/CD4 414AA-EYFP pair (Fig. 6B) . The BRET signal previously observed with these two proteins was also abrogated by the two CD4 In this work, for the first time, the direct interaction between the HIV-1 Nef protein and the human CD4 receptor was studied with wild-type proteins in human cells. By using the BRET technology, we directly detected the Nef-CD4 interaction in metabolically active cells and at physiological temperature. Surprisingly, we also observed the association of Nef with the CD4 414AA mutant. Although the fusion of Rluc and EYFP to Nef protein reduces its ability to down-regulate the membrane expression of CD4, and the CD4-EYFP fusion renders the receptor resistant to down-regulation, reproducible luminescence energy transfers between Nef-Rluc and CD4-EYFP or CD4 414AA-EYFP were detected. Compared to the BRET signal observed in prokaryotic cells as a result of homodimerization of circadian clock proteins (55) , the signals revealing homo-oligomerization (4, 14, 36; our results obtained for the Nef dimerization) and hetero-oligomerization (36; our results obtained for the Nef-CD4 interaction) of proteins in eukaryotic cells are smaller, but remain sufficient to detect protein-protein interactions in human cells. The specificity of this weak signal could be questioned as an increased proximity (A) Ten million cells were transfected with 15 g of plasmid coding for CD4, CD4 414AA, or the pCi-Neo empty plasmid and 2.5 g pCiNeo/Nef-Rluc and 2.5 g pCi-Neo/CD4-EYFP; as a negative control, cells were transfected with 15 g pCi-Neo, 2.5 g pCi-Neo/Nef-Rluc, and 2.5 g pHIS/␤2AdrR-EYFP. Two days after transfection, BRET experiments were realized. After subtraction of the negative control spectrum from the sample one, the previously observed EYFP signal in cells expressing Nef-Rluc and CD4-EYFP was abrogated in the presence of the nonfluorescent receptors CD4 and CD4 414AA. (B) The same experiment was performed with the pCi-Neo/CD4 414AA-EYFP plasmid. The EYFP signal generated with Nef-Rluc/CD4 414AA-EYFP pair was not detected anymore when CD4 or CD4 414AA was coexpressed.
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of CD4 and Nef could be due to lipid rafts localization of the two molecules. However, recent results strongly suggest that rafts do not significantly contribute to the effects of Nef on CD4 (48), although opposite conclusions were also reported (3). Moreover, one of the negative controls presented, ␤2Adr-EYFP, is also present in rafts, and energy transfer was not detected. A second transmembrane protein control also localized in rafts, CD8-EYFP, was used, and in the presence of Nef-Rluc, no BRET signal was measured (data not shown); however, the membrane concentration of CD8-EYFP being much lower than that of CD4-EYFP, it is thus difficult to compare these two conditions. As a complementary evaluation of the specificity of the Nef-CD4 interaction, competition experiments were done either with the wild-type CD4 or the CD4 414AA mutant and BRET signals were completely abolished. The fact that Nef-Rluc has a lower capacity to down-regulate CD4 and that CD4-EYFP cannot be down-regulated by Nef could have facilitated the detection of Nef/CD4 complex by BRET, maybe by increasing the Nef/CD4 complex half-life. Unfortunately, BRET could not be directly visualized by confocal microscopy, but we observed that, in our model Nef and the CD4 receptors colocalized at the plasma membrane, and the interactions are likely to occur at this site, as proposed previously (1, 11, 22, 38) . Nevertheless, the existence of these interactions was confirmed by a different approach, using the coimmunoprecipitation method, not only with fusion proteins but also with full-length, wild-type proteins, indicating that complex formation is not restricted to the modified proteins. Our results clearly demonstrate that Nef and CD4 proteins interact in human cells. Our data also confirm that the dileucine motif of the cytoplasmic domain of CD4 is critical for the Nef-induced CD4 downregulation. Nevertheless, we demonstrated that these residues are not implicated in the Nef/CD4 complex formation. This observation differs from those obtained in previous NMR experiments. However, data published during the final stage of our work (9) are in agreement with our result. Bentham et al. performed binding assays with a NefGST protein and fulllength CD4 and CD4 414 receptors in Sf9 insect cells or in vitro. Although the NefGST did not induce CD4 down-modulation in Sf9 cells, the authors reported that NefGST formed a complex with CD4 and CD4 414AA. In the human HeLa cells, the NefGST protein was able to bind CD4 414AA but failed to form a stable complex with the wild-type CD4, most likely due to the transient nature of this interaction in these conditions. The results of this group and ours indicate that the dileucine motif of the CD4 cytoplasmic tail is not involved in the Nef-CD4 interaction. This motif is indispensable for the CD4 internalization and could be presumably implicated in the connection of the Nef/CD4 complex to the endocytic machinery. Our results show that the DSP cross-linker and the BRET technique allow us to observe this Nef-CD4 interaction in human cells. Thus, the experimental procedures we developed appear as efficacious systems to study the molecular bases of the Nef/CD4 complex formation.
The Nef-CD4 interaction might be an important step in Nef-mediated CD4 downregulation, which is a key function for this early viral protein. Nef has been shown to enhance HIV replication (21, 33) and to evolve during progression to AIDS, acquiring an augmented capacity to deregulate CD4 (12) .
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